Quibim & Medical Horizons

 

Medical Horizons and Quibim Forge New Partnership to Bring QP-Prostate® and QP-Liver® AI Solutions to Italian Radiology

Florence, July 2025

Medical Horizons, a leading European distributor of AI-driven medical imaging solutions, proudly announces a strategic partnership with Quibim, a Spanish pioneer in quantitative imaging biomarkers. This multi-year Distribution Agreement secures Medical Horizons as leader in promoting and implementing QP-Prostate® and QP-Liver® across Italy, Eastern Europe, and the Middle East.

About Quibim

Founded in 2015 and now operating from offices in Spain, the UK and the US, Quibim (Quantitative Imaging Biomarkers in Medicine) has emerged as a global leader in developing deep-learning tools that convert routine MRI data into actionable, quantitative biomarkers  .

• QP-Prostate®

  • Automates prostate MRI quality checks, zonal segmentation and lesion detection.

  • Trained on biopsy-verified ground truth, the software boosts radiologist sensitivity by up to 10 percentage points, reaching detection rates close to 94 %  .

  • Recently received FDA 510(k) clearance as a combined CADe/CADx device after a multi-centre validation study at Mass General Brigham showed superior reader performance  .

• QP-Liver®

  • Delivers fully automatic whole-liver segmentation on multi-echo MRI, generating voxel-wise fat-fraction and iron-concentration maps.

  • Holds CE and UKCA marks and is designed to support early detection and longitudinal management of steatosis and iron overload—conditions that together drive a large share of the EU liver-disease burden  .

Medical Horizons, led by CEO Guido Osti and Product Manager Rolando Arpi, has built a reputation for clinically advanced AI technology. The new agreement positions the company as Quibim’s distribution and service hub for Italy, with initial deployments planned at italian centres of excellence. “Quibim complements our mission to deliver real-world AI that improves diagnostic confidence and patient outcomes,” said Guido Osti. “By adding QP-Prostate and QP-Liver to our portfolio, we can offer Italian clinicians a seamless, quantitative workflow from acquisition to report.”

Javier Pizcuera, Quibim’s Director of Global Business Development added:  “Medical Horizons has proven its ability to translate AI innovation into clinical value. Their expertise and hospital network make them the ideal partner to accelerate adoption of our prostate and liver solutions in one of Europe’s most sophisticated imaging markets.”

Shared Vision for Precision Diagnostics

The partnership underscores both companies’ commitment to:

• Evidence-based AI grounded in pathology and multi-omics correlations.

• Regulatory maturity, with CE and FDA clearances that support reimbursement pathways.

• Scalable cloud and on-premise deployment, ensuring interoperability with Italian PACS/VNA infrastructures.

Over the coming months Medical Horizons’ engineering team will integrate Quibim’s AI with local radiology workflows, provide Italian-language training and offer on-site clinical validation support.